echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The world's first 14-valent HPV vaccine! Shenzhou cell SCT1000 enters the clinic

    The world's first 14-valent HPV vaccine! Shenzhou cell SCT1000 enters the clinic

    • Last Update: 2021-08-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Shenzhou Cell announced that its self-developed 14-valent HPV vaccine SCT1000 has entered clinical phase I/II studies and completed the enrollment of all 80 subjects


    It is reported that Shenzhou Cell has been listed on the Science and Technology Innovation Board on June 23


    Currently, HPV vaccines on the domestic market include: Merck’s quadrivalent vaccine and 9-valent vaccine, GSK and Wantai Biological’s bivalent vaccine


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.